# US 2021/0260068 A1 · Dpp iv inhibitor formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260068 A1
- Document ID: US20210260068A1
- Status: Published application
- Kind: A1
- Application number: 17/319,325
- Filed: 2021-05-13
- Published: 2021-08-26
- Earliest claimed: 2006-05-04
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Anja KOHLRAUSCH; Patrick ROMER; Gerd SEIFFERT
- Web page: https://patentgrep.com/patent/US20210260068A1

## CPC

- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 9/2813: {Inorganic compounds}
- A61K 9/2853: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

## Claims

### Claim 1

A pharmaceutical composition comprising as an active ingredient a DPP IV inhibitor compound of formula
or a salt thereof, a first diluent, a second diluent, a binder, a disintegrant and a lubricant, wherein the first and second diluents are independently erythritol, low substituted hydroxypropyl cellulose, mannitol, pregelatinized starch, or xylitol.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first and second diluents are independently low substituted hydroxypropyl cellulose, mannitol, or pregelatinized starch.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the lubricant is talc, polyethyleneglycol, calcium behenate, calcium stearate, hydrogenated castor oil, or Magnesium stearate.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the binder is copovidone (copolymerisates of vinylpyrrolidon with other vinylderivates), hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), or polyvinylpyrrolidon (Povidone).

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the disintegrant is corn starch.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first diluent is mannitol, the second diluent is pregelatinized starch, the binder is copovidone, the disintegrant is corn starch, and the lubricant is magnesium stearate.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1 further comprising an additional disintegrant.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the additional disintegrant is crospovidone.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1 further comprising a glidant.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the glidant is colloidal silicon dioxide.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1 comprising
0.5-20%
active ingredient
40-88%
diluent 1,
3-40%
diluent 2,
1-5%
binder,
5-15%
disintegrant, and
0.1-4%
lubricant

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1 comprising
0.5-7%
active ingredient
50-75%
diluent 1,
5-15%
diluent 2,
2-4%
binder,
8-12%
disintegrant, and
0.5-2%
lubricant

### Claim 13 (depends on 1)

The pharmaceutical composition according to claim 1 in the dosage form of a capsule, a tablet, or a film-coated tablet.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13 comprising 2-4% film coat.

### Claim 15 (depends on 13)

The pharmaceutical composition of claim 13, wherein the film coat comprises a film-forming agent, a plasticizer, a glidant and optionally one or more pigments.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the film coat comprises hydroxypropylmethylcellulose (HPMC), polyethylene glycol (PEG), talc, titanium dioxide and iron oxide.

### Claim 17 (depends on 1)

A process for the preparation of a pharmaceutical composition according to claim 1 comprising
a. dissolving a binder in a solvent to produce a granulation liquid;
b. blending a DPP-IV inhibitor, a diluent, and a disintegrant to produce a pre-mix;
c. moistening the pre-mix with the granulation liquid and subsequently granulating the moistened pre-mix;
d. optionally sieving the granulated pre-mix through a sieve with a mesh size of at least 1.0 mm;
e. drying the granulate at about 40-75° C. until the desired loss on drying value in the range of 1-5% is obtained;
f. sieving the dried granulate through a sieve with a mesh size of at least 0.6 mm;
g. adding lubricant to the granulate for final blending.

### Claim 18 (depends on 17)

The process according to claim 17 further comprising
h. compressing the final blend into tablet cores;
i. preparing a coating suspension;
j. coating the tablet cores with the coating suspension to a weight gain of about 2-4% to produce film-coated tablets.

### Claim 19 (depends on 17)

The process according to claim 17, wherein part of the exipients are added extragranular prior to the final blending of step g.

### Claim 20 (depends on 17)

The process according to claim 17, wherein the granulate produced in steps a-e is produced in a one pot high shear granulation process and subsequent drying in a one pot granulator.

### Claim 21 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first diluent is mannitol.

### Claim 22 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first diluent is pregelatinized starch.

### Claim 23 (depends on 1)

The pharmaceutical composition of claim 1, wherein the second diluent is low substituted hydroxypropyl cellulose.

### Claim 24 (depends on 1)

The pharmaceutical composition of claim 1, wherein the second diluent is pregelatinized starch.

### Claim 25 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first diluent is mannitol, and the second diluent is pregelatinized starch or low substituted hydroxypropyl cellulose.

### Claim 26 (depends on 1)

The pharmaceutical composition of claim 1, wherein the first diluent is mannitol, and the second diluent is pregelatinized starch.
